Will a “multivitamin” a day keep the “MASLD doctor” away?

TL;DR

This paper explores how vitamin cofactors might influence homocysteine levels and liver disease severity, suggesting potential therapeutic strategies for MASLD.

Contribution

The paper introduces a mathematical model to evaluate how vitamin cofactor replacement affects homocysteine metabolism in MASLD.

Findings

Homocysteine metabolism is linked to the histological severity of MASLD.

Replacing cofactors like pyridoxine and folate may lower homocysteine levels in MASLD patients.

Further studies are needed to confirm if modulating homocysteine is a viable MASLD treatment.

Abstract

This commentary discusses the results of a study that assessed the relationship between homocysteine metabolism and histological severity of metabolic dysfunction-associated steatotic liver disease (MASLD), and applied a mathematical model to examine how replacement with different cofactors (pyridoxine, cobalamin, betaine, and folate) may affect homocysteine levels in patients with MASLD. It highlights the clinical implications of the study and examines the pathophysiological support behind the detected associations. It also discusses its limitations, emphasizing the need for further longitudinal and interventional studies to confirm whether modulating homocysteine levels could be a viable therapeutic strategy for MASLD.

Figures